All posts by: Michael Zand

About Michael Zand

CRISPR-Cas9 Epigenome Editing Screen Reveals Regulatory Elements – GenomeWeb

Continue reading

2017-04-03 NEWS

CRISPR-Cas9 Epigenome Editing Screen Reveals Regulatory Elements
GenomeWeb
NEW YORK (GenomeWeb) – Researchers interested in untangling the functional roles of regulatory elements have a new screening tool at their disposal: a CRISPR-Cas9-based epigenomic editing scheme. In a study appearing online today in Nature …

Continue reading

2017-04-03 NEWS

#AACR17: Study Explores Best Time to Give CAR T Cell Therapy
Memorial Sloan Kettering Cancer Center (blog)
For patients with leukemia who relapse after chemotherapy, treatment options have traditionally been limited. At MSK, an experimental immunotherapy called CAR T therapy has expanded options for these patients. New research data presented at this year’s …

Continue reading

2017-04-03 NEWS

TIME

Immunotherapy May Treat This Deadly Breast Cancer
TIME
But in a new presentation at the annual American Association for Cancer Research meeting, researchers say that one of the latest immunotherapy drugs called atezolizumab, or Tecentriq, may help people with triple negative breast cancer to live longer.
First Survival Results With Immunotherapy, TNBCMedscape
Breast Cancer ‘Immunotherapy‘ Helps Some With Tough-to-Treat DiseaseArizona Daily Star
Triple-negative Breast Cancer Patients Who Responded to Immunotherapy Had Long-term Survival BenefitMilTech
OncLive
all 16 news articles »
Continue reading

2017-04-03 NEWS

Worldcrunch

The Shady Business Of Experimental Stem Cell Treatments
Worldcrunch
And yet patients often receive invitations from private clinics or doctors promising a miracle cure using stem cells, which can be multiplied in specialized settings or surfaces. “Patients are ready to enter into any protocol or clinical trial rather

and more »

Continue reading

2017-04-03 NEWS

Gene therapy trial launched for X-linked retinitis pigmentosa
ModernMedicine
Researchers have injected their first patient with a virus engineered to remodel the gene responsible for X-linked retinitis pigmentosa (XLRP). “If successful, this gene therapy has the potential to transform the lives of many patients,” said David